Stefan Maenz1, Olaf Brinkmann2, Elke Kunisch3, Victoria Horbert3, Francesca Gunnella3, Sabine Bischoff4, Harald Schubert4, Andre Sachse5, Long Xin3, Jens Günster6, Bernhard Illerhaus6, Klaus D Jandt1, Jörg Bossert1, Raimund W Kinne7, Matthias Bungartz2. 1. Materials Science, Otto Schott Institute of Materials Research, Friedrich Schiller University Jena, Löbdergraben 32, Jena D-07743, Germany. 2. Orthopedics, Department of Orthopedics, Jena University Hospital, Waldkrankenhaus "Rudolf Elle", Klosterlausnitzer Str. 81, Eisenberg D-07607, Germany; Experimental Rheumatology Unit, Department of Orthopedics, Jena University Hospital, Waldkrankenhaus "Rudolf Elle", Klosterlausnitzer Str. 81, Eisenberg D-07607, Germany. 3. Experimental Rheumatology Unit, Department of Orthopedics, Jena University Hospital, Waldkrankenhaus "Rudolf Elle", Klosterlausnitzer Str. 81, Eisenberg D-07607, Germany. 4. Institute of Laboratory Animal Sciences and Welfare, Jena University Hospital, Dornburger Str. 23, Jena D-07743, Germany. 5. Orthopedics, Department of Orthopedics, Jena University Hospital, Waldkrankenhaus "Rudolf Elle", Klosterlausnitzer Str. 81, Eisenberg D-07607, Germany. 6. Federal Institute for Materials Research and Testing (BAM), Unter den Eichen 87, Berlin D-12205, Germany. 7. Experimental Rheumatology Unit, Department of Orthopedics, Jena University Hospital, Waldkrankenhaus "Rudolf Elle", Klosterlausnitzer Str. 81, Eisenberg D-07607, Germany. Electronic address: raimund.w.kinne@med.uni-jena.de.
Abstract
BACKGROUND CONTEXT: Injectable, brushite-forming calcium phosphate cements (CPC) show potential for bone replacement, but they exhibit low mechanical strength. This study tested a CPC reinforced with poly(l-lactide-co-glycolide) acid (PLGA) fibers in a minimally invasive, sheep lumbar vertebroplasty model. PURPOSE: The study aimed to test the in vivo biocompatibility and osteogenic potential of a PLGA fiber-reinforced, brushite-forming CPC in a sheep large animal model. STUDY DESIGN/ SETTING: This is a prospective experimental animal study. METHODS: Bone defects (diameter: 5 mm) were placed in aged, osteopenic female sheep, and left empty (L2) or injected with pure CPC (L3) or PLGA fiber-reinforced CPC (L4; fiber diameter: 25 µm; length: 1 mm; 10% [wt/wt]). Three and 9 months postoperation (n=20 each), the structural and functional CPC effects on bone regeneration were documented ex vivo by osteodensitometry, histomorphometry, micro-computed tomography (micro-CT), and biomechanical testing. RESULTS: Addition of PLGA fibers enhanced CPC osteoconductivity and augmented bone formation. This was demonstrated by (1) significantly enhanced structural (bone volume/total volume, shown by micro-CT and histomorphometry; 3 or 9 months) and bone formation parameters (osteoid volume and osteoid surface; 9 months); (2) numerically enhanced bone mineral density (3 and 9 months) and biomechanical compression strength (9 months); and (3) numerically decreased bone erosion (eroded surface; 3 and 9 months). CONCLUSIONS: The PLGA fiber-reinforced CPC is highly biocompatible and its PLGA fiber component enhanced bone formation. Also, PLGA fibers improve the mechanical properties of brittle CPC, with potential applicability in load-bearing areas.
BACKGROUND CONTEXT: Injectable, brushite-forming calcium phosphate cements (CPC) show potential for bone replacement, but they exhibit low mechanical strength. This study tested a CPC reinforced with poly(l-lactide-co-glycolide) acid (PLGA) fibers in a minimally invasive, sheep lumbar vertebroplasty model. PURPOSE: The study aimed to test the in vivo biocompatibility and osteogenic potential of a PLGA fiber-reinforced, brushite-forming CPC in a sheep large animal model. STUDY DESIGN/ SETTING: This is a prospective experimental animal study. METHODS: Bone defects (diameter: 5 mm) were placed in aged, osteopenic female sheep, and left empty (L2) or injected with pure CPC (L3) or PLGA fiber-reinforced CPC (L4; fiber diameter: 25 µm; length: 1 mm; 10% [wt/wt]). Three and 9 months postoperation (n=20 each), the structural and functional CPC effects on bone regeneration were documented ex vivo by osteodensitometry, histomorphometry, micro-computed tomography (micro-CT), and biomechanical testing. RESULTS: Addition of PLGA fibers enhanced CPC osteoconductivity and augmented bone formation. This was demonstrated by (1) significantly enhanced structural (bone volume/total volume, shown by micro-CT and histomorphometry; 3 or 9 months) and bone formation parameters (osteoid volume and osteoid surface; 9 months); (2) numerically enhanced bone mineral density (3 and 9 months) and biomechanical compression strength (9 months); and (3) numerically decreased bone erosion (eroded surface; 3 and 9 months). CONCLUSIONS: The PLGA fiber-reinforced CPC is highly biocompatible and its PLGA fiber component enhanced bone formation. Also, PLGA fibers improve the mechanical properties of brittle CPC, with potential applicability in load-bearing areas.
Authors: Isabel R Dias; José A Camassa; João A Bordelo; Pedro S Babo; Carlos A Viegas; Nuno Dourado; Rui L Reis; Manuela E Gomes Journal: Curr Osteoporos Rep Date: 2018-04 Impact factor: 5.096
Authors: Stefan Maenz; Olaf Brinkmann; Raimund W Kinne; Matthias Bungartz; Ines Hasenbein; Christina Braun; Elke Kunisch; Victoria Horbert; Francesca Gunnella; André Sachse; Sabine Bischoff; Harald Schubert; Klaus D Jandt; Jörg Bossert; Dominik Driesch Journal: J Bone Miner Metab Date: 2020-04-15 Impact factor: 2.626
Authors: Francesca Gunnella; Elke Kunisch; Victoria Horbert; Stefan Maenz; Jörg Bossert; Klaus D Jandt; Frank Plöger; Raimund W Kinne Journal: Pharmaceutics Date: 2019-09-03 Impact factor: 6.321
Authors: Jorge A Mojica-Santiago; Gernot M Lang; Rodrigo Navarro-Ramirez; Ibrahim Hussain; Roger Hӓrtl; Lawrence J Bonassar Journal: JOR Spine Date: 2018-08-30
Authors: Ines Hasenbein; André Sachse; Peter Hortschansky; Klaus D Schmuck; Victoria Horbert; Christoph Anders; Thomas Lehmann; René Huber; Alexander Maslaris; Frank Layher; Christina Braun; Andreas Roth; Frank Plöger; Raimund W Kinne Journal: Biomedicines Date: 2022-02-21